%0 Journal Article
%T The EFEMEREYE Study: prenatal medication exposure and ocular anomaly occurrence in EFEMERIS health database.
%A Dubucs C
%A N'Go V
%A Caillet A
%A Cifuentes EA
%A Beau AB
%A Frémont F
%A Hurault-Delarue C
%A Courtade-Saïdi M
%A Damase-Michel C
%J J AAPOS
%V 28
%N 3
%D 2024 Jun 7
%M 38719141
%F 1.325
%R 10.1016/j.jaapos.2024.103931
%X <B>OBJECTIVE: </B>To describe ocular anomalies (OAs) in children and fetuses in a French general population, to estimate their prevalence, and to investigate a possible association between prenatal medication exposure and the occurrence of OA in utero or in early childhood.<BR><B>METHODS: </B>We conducted a case-control study using the EFEMERIS cohort, a database containing pregnancies registered in Haute-Garonne and their outcomes. We collected OA descriptions of fetuses at the time of pregnancy termination or of children at birth and the results of eye examinations of children at 9 months and 2 years of age.<BR><B>RESULTS: </B>The prevalence of overall OAs was 2.13%, of which 0.04% were congenital ocular malformations (COMs). A total of 2,968 cases and 136,619 controls were selected for analysis. There was a significant difference between the two groups with regard to prenatal exposure to medications for the digestive tract and metabolism, the cardiovascular system, and the respiratory system. Multivariable analysis revealed an increased risk of OA in children of mothers exposed to magnesium during and 1 month before pregnancy (OR = 1.24; 95% CI, 1.11-1.38).<BR><B>CONCLUSIONS: </B>This first pharmaco-epidemiological study on OA in France suggests that OA may be associated with exposure to commonly used medications. Given the rarity of COM, larger, international studies are warranted.